Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 1/20 | 0.60 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 3/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894930 | 0.82 | LIPC (0.66) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL3888815 | 0.80 | LIPC (0.63) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL25243656 | 0.80 | CYP1A2 (0.41) | LIPCLIPGPLK1ALDH1A1CYP2C19 | |
| SCHEMBL15635834 | 0.80 | LIPC (0.66) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL3889836 | 0.79 | LIPC (0.61) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL3888585 | 0.79 | LIPC (0.61) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL3885198 | 0.78 | KDM4E (0.59) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL3888029 | 0.78 | LIPC (0.60) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL3886144 | 0.77 | LIPC (0.58) | LIPCLIPGPLK1AKR1C3AKR1C2 | |
| SCHEMBL15636031 | 0.77 | LIPC (0.63) | LIPCLIPGPLK1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT | 2006-06-22 | — | — | US | disclosed |
| US-7045521-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT (US) | 2004-06-10 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1343751-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
| WO-2002060859-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | LIPC 2777/4885LIPG 561/4885PLK1 4448/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | LIPC 2777/4885LIPG 561/4885PLK1 4448/4885 |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | LIPC 2767/4885LIPG 507/4885PLK1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.